Vanda gains easy panel backing for tasimelteon
This article was originally published in Scrip
Executive Summary
Vanda Pharmaceuticals had a relatively easy time of it at the 14 November meeting of the FDA's Peripheral and Central Nervous Systems Drugs Advisory Committee (PCNSAC), which backed approval of the company's experimental drug tasimelteon as a circadian regulator to treat non-24-Hour disorder (non-24) in patients with total blindness.